CORRECTION: RedHill News From Tues. Was 2 Abstracts Related To Phase III GUARD Study Of BEKINDA 24 mg Accepted For Oral Presentations At SAEM '18 Meeting; The initial headline suggested the trial met primary endpoint; this was reported in Jun. '17
Paul Quintaro